HomeCompareWKGBF vs ABBV

WKGBF vs ABBV: Dividend Comparison 2026

WKGBF yields 1.39% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $79.9K in total portfolio value
10 years
WKGBF
WKGBF
● Live price
1.39%
Share price
$1.45
Annual div
$0.02
5Y div CAGR
5.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.4K
Annual income
$274.95
Full WKGBF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WKGBF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWKGBFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WKGBF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WKGBF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WKGBF
Annual income on $10K today (after 15% tax)
$118.24/yr
After 10yr DRIP, annual income (after tax)
$233.71/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,822.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WKGBF + ABBV for your $10,000?

WKGBF: 50%ABBV: 50%
100% ABBV50/50100% WKGBF
Portfolio after 10yr
$62.4K
Annual income
$12,523.36/yr
Blended yield
20.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WKGBF
No analyst data
Altman Z
4.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WKGBF buys
0
ABBV buys
0
No recent congressional trades found for WKGBF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWKGBFABBV
Forward yield1.39%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.8%40.6%
Portfolio after 10y$22.4K$102.3K
Annual income after 10y$274.95$24,771.77
Total dividends collected$2.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WKGBF vs ABBV ($10,000, DRIP)

YearWKGBF PortfolioWKGBF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,847$147.17$11,550$430.00$703.00ABBV
2$11,764$157.85$13,472$627.96$1.7KABBV
3$12,757$169.27$15,906$926.08$3.1KABBV
4$13,832$181.50$19,071$1,382.55$5.2KABBV
5$14,994$194.58$23,302$2,095.81$8.3KABBV
6$16,253$208.57$29,150$3,237.93$12.9KABBV
7$17,614$223.54$37,536$5,121.41$19.9KABBV
8$19,086$239.54$50,079$8,338.38$31.0KABBV
9$20,679$256.66$69,753$14,065.80$49.1KABBV
10$22,401$274.95$102,337$24,771.77$79.9KABBV

WKGBF vs ABBV: Complete Analysis 2026

WKGBFStock

Sanderson Design Group plc designs, manufactures, markets, and distributes interior furnishings, fabrics, and wallpapers worldwide. The company operates in two segments, Brands and Manufacturing. The Brands segment designs, markets, sells, distributes, and licenses Sanderson, Morris & Co., Harlequin, Zoffany, Scion, Clarke & Clarke, and Archive by Sanderson Design brands. This segment offers wallpapers and fabrics, homewares, window coverings, furniture items, bedding products, cushions, rugs, paints, tableware, scarfs, and leather goods. The Manufacturing segment manufactures wallcoverings and printed fabrics. The company operates showrooms in Chelsea Harbour, London; and Manhattan, New York. It serves designers, retailers, distributors, and architects. The company was formerly known as Walker Greenbank PLC and changed its name to Sanderson Design Group plc in November 2020. Sanderson Design Group plc was incorporated in 1899 and is headquartered in Denham, the United Kingdom.

Full WKGBF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WKGBF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WKGBF vs SCHDWKGBF vs JEPIWKGBF vs OWKGBF vs KOWKGBF vs MAINWKGBF vs JNJWKGBF vs MRKWKGBF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.